Impact of methotrexate-dosing regimens for GVHD prophylaxis on clinical outcomes of HLA-matched allogeneic HSCT.

ABSTRACT: Severe graft-versus-host disease (GVHD) remains a major complication of allogeneic haematopoietic stem cell transplantation (allo-HSCT), necessitating optimal immunosuppressive strategies. This retrospective study used data from the Japanese Transplant Registry Unified Management Program to compare three methotrexate (MTX)-dosing regimens for GVHD prophylaxis in patients undergoing human leucocyte antigen (HLA)-matched allo-HSCT: a low-dose 3-day regimen (Ld3:10 mg/m² on day 1, 7 mg/m² on days 3 and 6), a low-dose 4-day regimen (Ld4: Ld3 with an additional 7 mg/m² on day 11) and an original-dose 3-day regimen (Od3: 15 mg/m² on day 1, 10 mg/m² on days 3 and 6). Among 2537 analysed patients, Ld3 was the most commonly used regimen. Multiv

SUBMITTER: Suzuki T 

PROVIDER: S-EPMC12819093 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature